Filing Flows › BioCorRx (BICX) › Q3 2025
BioCorRx (BICX) Q3 2025 earnings results (third quarter 2025)
10-Q filed Nov 14, 2025
BioCorRx (BICX) reported revenue of $635K for the third quarter 2025 (Q3 2025) and +256% from the quarter before. Operating margin was -306.3%, net loss $809K (127.3% of revenue).
BioCorRx, Q3 2025: revenue $635K, operating margin -306.3%, net loss $809K, operating cash flow −$634K. The chart follows the revenue to costs, profit and cash.
| Q3 2025 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $635K | +256% | — |
| Operating profit | −$1.9M | — | — |
| Net earnings | −$809K | — | — |
| Operating cash flow | −$634K | — | — |
What changed
Revenue was $635K in Q3 2025, up 256% from the previous quarter.
Operating costs exceeded revenue by $1.9M, an operating margin of -306.3%. The quarter ended with a net loss of $809K, after a profit of $1.4M the previous quarter. Non-operating items added $1.1M, -141% of pre-tax earnings, so the bottom line overstates operating performance.
Operating cash flow was −$634K. Non-cash charges added back $72K of depreciation and amortization. Working capital and other items added $102K.
Questions
What was BioCorRx's revenue in the third quarter 2025?
BioCorRx (BICX) reported revenue of $635K for the third quarter 2025 (Q3 2025) and +256% from the quarter before.
Was BioCorRx profitable in the third quarter 2025?
Operating loss was $1.9M (-306.3% of revenue) and net loss $809K.
Source: BioCorRx 10-Q on SEC EDGAR.